'Future planning is impossible,' says Greek pharma boss

29 April 2019
greece-big-2

The fact that Greece has regained its financial independence after an eight-year bailout program does not mean that the crisis is over in the country’s pharma market, according to Olympios Papadimitriou.

Mr Papadimitriou is president of Greek pharma association Hellenic Association of Pharmaceutical Companies (SFEE), which together with the Foundation for Economic and Industrial Research, has published a report entitled The Greek pharmaceutical market: Facts and figures 2018.

The annual report reviews the main data, developments and trends in the area of pharmaceuticals and healthcare in general, in Greece and in Europe. The focus is on the structure and performance of the industry.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical